SMS PHARMACEUTICALS LTD. - 532815 - Corporate Action-Board approves Dividend
Recommended the Dividend of 30% per equity share of face value of Rs. 1/-each for the financial year 2021-2230-05-2022
30-05-2022
SMS PHARMACEUTICALS LTD. - 532815 - Board Meeting Outcome for Outcome Of Board Meeting Held On 30Th May, 2022
Outcome of Board Meeting held on 30th May, 202230-05-2022
SMS PHARMACEUTICALS LTD. - 532815 - Board to consider Dividend
SMS Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company scheduled to be held on May 30, 2022, inter alia, to transact the following items:1. To consider and approve the Audited Financial Results (Standalone & Consolidated) for the Fourth Quarter and Financial Year ended March 31, 2022.2. To consider, recommend dividend if any for the financial year 2021-2022.In accordance with the Company''s Code of Conduct for Prevention of Insider Trading, pursuant to the amended SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has already intimated its designated persons including directors regarding the closure of the ''Trading Window'' for trading in the Company''s equity shares from April 01, 2022, it willremain closed up to June 01, 2022 (both days inclusive) and shall be re-opened on June 02, 2022.23-05-2022
SMS PHARMACEUTICALS LTD. - 532815 - Board Meeting Intimation for Notice Of Board Meeting & Intimation
SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 ,inter alia, to consider and approve Notice of Board Meeting & Intimation23-05-2022
SMS PHARMACEUTICALS LTD. - 532815 - Approval For Reclassification Of Shareholders From 'Promoter And Promoter Group' To 'Public' Category Under Regulation 31A Of SEBI (LODR) Regulations, 2015
Approval for Reclassification of shareholders from 'Promoter and Promoter Group' to 'Public' category under Regulation 31A of SEBI (LODR) Regulations, 201506-05-2022
SMS PHARMACEUTICALS LTD. - 532815 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySMS PHARMACEUTICALS LTD. 2CINL24239TG1987PLC008066 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 259.36 4Highest Credit Rating during the previous FY A 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Thirumalesh Tumma Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: T. Lakshmi Narayana Designation: Chief Financial Officer EmailId: [email protected] Date: 29/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.29-04-2022
SMS PHARMACEUTICALS LTD. - 532815 - Compliance Certificate Under Regulation 7(3) Of SEBI (LODR), Regulations, 2015
Compliance Certificate under Regulation 7(3) of SEBI (LODR), Regulations, 201516-04-2022
SMS PHARMACEUTICALS LTD. - 532815 - Compliance Certificate Under Regulation 40(9)&(10) Of SEBI (LODR) Regulations, 2015
Compliance Certificate under Regulation 40(9)&(10) of SEBI (LODR) Regulations, 201515-04-2022
SMS PHARMACEUTICALS LTD. - 532815 - Revised Disclosure- Confirmation Of Not Falling Under Large Corporate
Revised Disclosure- Confirmation of not falling under Large Corporate Criteria13-04-2022